Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock
Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock. 4th line drug approval was approved! GISTer Sarah McGoram shares the news.
Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock. 4th line drug approval was approved! GISTer Sarah McGoram shares the news.
Concerning Medicare Open Enrollment: It is especially important for GIST patients to carefully consider available plans, as one of the financial support resources that has been available through Novartis Pharmaceuticals will end on January 1, 2021.
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.
This discussion reviewed CRCI in general, and how a person who is being treated for GIST could be affected. We also talked about strategies that can help ameliorate CRCI, new research on CRCI and GIST. we also gave advice on how cancer survivors can best cope with and care for themselves during this unusual global health event.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.
Drug repository programs have the potential to be a key component in accessing life-saving treatments. In a landscape where prices for cancer drugs are escalating, many face a challenge in obtaining life-saving treatments. There are many resources for overcoming these obstacles, but it is clearly not enough for those already struggling with the challenges of a cancer diagnosis.